Nektar Therapeutics

NKTR Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of NKTR by members of U.S. Congress

Politician Type Traded
Ro Khanna House / D Purchase $1,001 - $15,000 N/A
Ro Khanna House / D Sale $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 Sep 16, 2019
Ro Khanna House / D Sale $1,001 - $15,000 Jun 05, 2019
Ro Khanna House / D Purchase $1,001 - $15,000 Jun 03, 2019
Josh Gottheimer House / D Sale $1,001 - $15,000 Jun 21, 2018
Josh Gottheimer House / D Purchase $1,001 - $15,000 Jun 06, 2018
Ro Khanna House / D Sale $1,001 - $15,000 May 08, 2018
Ro Khanna House / D None $1,001 - $15,000 Apr 03, 2018
NKTR Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
NKTR Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
NKTR Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in NKTR holdings by institutional investors

Insider Trading

Quarterly net insider trading by NKTR's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $50,000 Jan 20, 2022 Issue: Health Issues
  • $50,000 Oct 20, 2021 Issue: Health Issues
  • $50,000 Jul 20, 2021 Issue: Health Issues
  • $50,000 Apr 20, 2021 Issue: Health Issues
  • $50,000 Jan 21, 2021 Issue: Health Issues
  • $50,000 Oct 20, 2020 Issue: Health Issues
  • $60,000 Jul 20, 2020 Issue: Health Issues
  • $14,000 Jul 20, 2020 Issue: Pharmacy
  • $60,000 Apr 26, 2020 Issue: Health Issues
  • $60,000 Feb 25, 2020 Issue: Health Issues
  • $50,000 Jan 21, 2020 Issue: Health Issues
  • $14,000 Jan 15, 2020 Issue: Pharmacy
  • $20,000 Jan 10, 2020 Issue: Pharmacy
  • $20,000 Oct 16, 2019 Issue: Pharmacy
  • $50,000 Oct 08, 2019 Issue: Health Issues
  • $50,000 Jul 18, 2019 Issue: Health Issues
  • $20,000 Jul 15, 2019 Issue: Pharmacy
  • $50,000 Apr 12, 2019 Issue: Health Issues
  • $20,000 Apr 11, 2019 Issue: Pharmacy
  • $50,000 Jan 20, 2019 Issue: Health Issues
  • $20,000 Jan 18, 2019 Issue: Pharmacy
  • $20,000 Oct 18, 2018 Issue: Pharmacy
  • $50,000 Oct 16, 2018 Issue: Health Issues
  • $108,000 Oct 16, 2018 Issue: Pharmacy
  • $20,000 Jul 20, 2018 Issue: Taxation/Internal Revenue Code Pharmacy
  • $50,000 Jul 20, 2018 Issue: Health Issues
  • $21,600 Jul 18, 2018 Issue: Pharmacy
  • $20,000 Apr 20, 2018 Issue: Taxation/Internal Revenue Code Pharmacy
  • $60,000 Apr 18, 2018 Issue: Health Issues
  • $72,000 Apr 17, 2018 Issue: Pharmacy
  • $20,000 Jan 22, 2018 Issue: Taxation/Internal Revenue Code Pharmacy
  • $144,000 Jan 19, 2018 Issue: Pharmacy
  • $30,000 Jan 18, 2018 Issue: Health Issues
  • $20,000 Oct 20, 2017 Issue: Taxation/Internal Revenue Code Pharmacy
  • $20,000 Oct 20, 2017 Issue: Pharmacy
  • $30,000 Oct 13, 2017 Issue: Health Issues
  • $20,000 Apr 20, 2017 Issue: Pharmacy
  • $60,000 Apr 01, 2017 Issue: Pharmacy
  • $20,000 Jan 23, 2017 Issue: Pharmacy
  • $60,000 Jan 19, 2017 Issue: Pharmacy
  • $20,000 Oct 20, 2016 Issue: Pharmacy
  • $60,000 Oct 20, 2016 Issue: Pharmacy
  • $20,000 Jul 20, 2016 Issue: Pharmacy
  • $60,000 Jul 20, 2016 Issue: Pharmacy
  • $20,000 Apr 20, 2016 Issue: Pharmacy
  • $60,000 Apr 20, 2016 Issue: Pharmacy
  • $10,000 Jan 20, 2016 Issue: Pharmacy
  • $90,000 Jan 20, 2016 Issue: Pharmacy
  • $90,000 Oct 20, 2015 Issue: Pharmacy
  • $90,000 Jul 20, 2015 Issue: Pharmacy
  • $90,000 Apr 20, 2015 Issue: Pharmacy
  • $100,000 Jan 20, 2015 Issue: Pharmacy
  • $90,000 Oct 20, 2014 Issue: Pharmacy
  • $90,000 Jul 21, 2014 Issue: Pharmacy
  • $10,000 Oct 01, 2008 Issue: Health Issues
  • $10,000 Jul 18, 2008 Issue: Health Issues
Corporate Lobbying

NKTR Estimated quarterly lobbying spending

Revenue Breakdown

NKTR Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
NKTR Income Statement
NKTR Balance Sheet
NKTR Cash Flow
U.S. Patents

New NKTR patent grants

  • Patent Title: Polymer-factor viii moiety conjugates Jun. 19, 2018
  • Patent Title: Polymer-semaxanib moiety conjugates Apr. 17, 2018
  • Patent Title: Oligomer-containing benzamide-based compounds Apr. 10, 2018
  • Patent Title: Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound Mar. 27, 2018
  • Patent Title: Method for preparing a polymeric reagent Mar. 13, 2018
  • Patent Title: Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method Mar. 06, 2018
  • Patent Title: N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides Mar. 06, 2018
  • Patent Title: Conjugates of an il-2 moiety and a polymer Jan. 09, 2018
  • Patent Title: Polymer-active agent conjugate Dec. 12, 2017
  • Patent Title: N-maleimidyl polymer derivatives Nov. 28, 2017
  • Patent Title: Polymer-sunitinib conjugates Nov. 28, 2017
  • Patent Title: Oligomer-opioid agonist conjugates Nov. 28, 2017
  • Patent Title: Kappa opioid agonists and uses thereof Nov. 14, 2017
  • Patent Title: Multi-arm polymer prodrugs Nov. 07, 2017
  • Patent Title: Methods for treating humans having brain cancer Oct. 31, 2017
  • Patent Title: Oligomer-beta blocker conjugates Oct. 10, 2017
  • Patent Title: Composition comprising a polymeric reagent Oct. 03, 2017
  • Patent Title: Polymer conjugates of protegrin peptides Sep. 19, 2017
  • Patent Title: Methods for preparing polymeric reagents and compositions of polymeric reagents Aug. 15, 2017
  • Patent Title: Oligomer-tricyclic conjugates Aug. 08, 2017
  • Patent Title: Particulate materials Jul. 11, 2017
  • Patent Title: Opioid agonists and uses thereof Jun. 27, 2017
  • Patent Title: Solid salt form of α-6-mpeg Jun. 20, 2017
  • Patent Title: Negatively biased sealed nebulizer systems and methods Jun. 20, 2017
  • Patent Title: Polymer conjugates of therapeutic peptides Jun. 20, 2017
  • Patent Title: Aerosolization device Jun. 13, 2017
  • Patent Title: Oligomer-foscarnet conjugates Jun. 06, 2017
  • Patent Title: Conjugates of an anti-tnf-alpha antibody May. 02, 2017
  • Patent Title: Oligomer-containing substituted aromatic triazine compounds Apr. 11, 2017
  • Patent Title: N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides Apr. 11, 2017
  • Patent Title: Particulate materials Apr. 11, 2017
  • Patent Title: Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method Feb. 28, 2017
  • Patent Title: Oligomer-containing hydantoin compounds Jan. 10, 2017
  • Patent Title: Compositions comprising two different populations of polymer-active agent conjugates Jan. 10, 2017
  • Patent Title: Systems and methods for driving nebulizers Jan. 03, 2017
  • Patent Title: Oligomer-opioid agonist conjugates Dec. 06, 2016
  • Patent Title: Multi-arm polymeric alkanoate conjugates Nov. 29, 2016
  • Patent Title: N-maleimidyl polymer derivatives Nov. 15, 2016
  • Patent Title: Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage Nov. 15, 2016
  • Patent Title: Oligomer-amino acid conjugates Nov. 08, 2016
  • Patent Title: Oligomer-opioid agonist conjugates Oct. 04, 2016
  • Patent Title: Polymer-based compositions and conjugates of hiv entry inhibitors Sep. 20, 2016
  • Patent Title: Conjugates of small-interfering nucleic acids Sep. 06, 2016
  • Patent Title: Oligomer-calcimimetic conjugates and related compunds Aug. 23, 2016
  • Patent Title: Oligomer modified diaromatic substituted compounds Aug. 23, 2016
  • Patent Title: Compositions comprising a polymeric reagent and a pharmacologically active agent Jul. 26, 2016
  • Patent Title: Oligomer-containing pyrrolidine compounds Jul. 26, 2016
  • Patent Title: Chemically modified small molecules Jul. 12, 2016
  • Patent Title: Methods for preparing polymeric reagents Jul. 05, 2016
  • Patent Title: Oligomer-containing benzamide-based compounds Jun. 28, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to NKTR from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
NKTR News

Recent insights relating to NKTR

CNBC Recommendations

Recent picks made for NKTR stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in NKTR

NKTR Analyst Ratings

NKTR Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
NKTR Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $NKTR stock a Buy, Sell, or Hold?

  • What is the price target for $NKTR stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

NKTR Top Shareholders
Shareholder
Shares Held
NKTR Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $NKTR stock?

  • Who owns the most shares of $NKTR stock?

  • What funds own $NKTR stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

NKTR Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view NKTR Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About NKTR

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

  • Address San Francisco, CA
  • Market Cap 1.1 billion
  • Employees 61
  • Industrial Classification Pharmaceutical Preparations
Back To Top